WuXi Apptec Resumes Operations at Wuhan Site
The facility, which handles discovery chemistry services, will accelerate its operations over the next few weeks while taking precautions to guarantee the health and safety of its employees across every site.
WuXi AppTec announced on March 10, 2020 that it has resumed operations at its Wuhan, China, site in agreement with local regulations and global novel coronavirus (COVID-19) health and safety guidelines.
According to a company press release, the facility, which handles discovery chemistry services, will accelerate its operations over the next few weeks while taking precautions to guarantee the health and safety of its employees across every site.
“We are working with our employees and suppliers to reach steady state operations at our Wuhan site as soon as possible,” said Steve Yang, executive vice-president and chief business officer of WuXi AppTec, in a company press release. “We value our customers’ contributions to the healthcare field and put them first by providing timely and world-class quality service and continue to do the right thing for patients-a goal that WuXi AppTec has pursued since its founding.”
Source: WuXi AppTec
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
